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Taiwanwas used in this study. There are three screening tools: 1) Pap smear alone;
2) HPV DNA testing followed by Pap smear triage; and 3) self-sampling for HPV
testing followed by Pap smear triage. Self-sampling for HPV testing strategy is
annual, and another strategies of screening intervals are annually, every 3 years,
and every 5 years. The model parameters are collected from the published refer-
ences and the health-related governments in Taiwan. Outcomemeasures included
life expectancy, quality-adjusted life years (QALYs), lifetime costs, and incremental
cost-effectiveness ratios (ICERs). Probabilistic sensitivity analyses (PSAs) were con-
ducted to assess parameter uncertainty. RESULTS: When three times GDP per
capita is used as the decision threshold, and all seven screening strategies were
cost-effective compared with the no-screening strategy. Compared with the pri-
mary screening strategy (an annual Pap smear), self-samplingHPV testing followed
by Pap smear triage, HPV DNA testing followed by Pap smear triage every 5 years
and every 3 years were cost-effective. CONCLUSIONS: Self-sampling for HPV testing
followed by Pap smear triage is one of the cost-effective screening strategies in Taiwan.
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OBJECTIVES:Gefitinib is an effective targeted therapy for a subset of non-small cell
lung cancer (NSCLC) patients, although its cost-effectiveness remains controver-
sial.. This study used national health insurance claims data to evaluate the cost-
effectiveness of gefinitib in patients with NSCLC in Taiwan. METHODS: Using
claims data and enrollment record from the 2002-2009 National Health Insurance
Research Database (NHIRD) in Taiwan, we identified lung cancer patients via the
ICD-9-CM codes.We then used ICD-9-CM and billing codes to identify patients who
had received chemotherapy containing plantinum-based regimens followed by
taxane-based regimens between November 1, 2004 and October 31, 2007. We de-
fined the index date as the date of 1st claim for taxane-based chemotherapy and
limited the observational period for cost and survival to 2 years after index date.We
further classified these patients into two groups: those who had subsequently
received gefitinib vs those had not. We determined survival status by using a pre-
viously developed algorithm using the enrollment file of the NHIRD and converted
direct medical costs to 2011 US dollars. We then calculated the net benefit for each
patient by applying various willingness-to-pay (WTP) values and employed the net
benefit regression approach to assess the cost-effectiveness of gefitinib. RESULTS:
We identified 2555 lung cancer; 979 (38%) had received gefitinib during our study
period. The average cost (standard deviation) were 64150(29482) USD for the ge-
fitinib users and 35925(27360) for non-users. The average survival was 487 days
(228) for the gefitinib users and 291 days (248) for non-users. Net benefit regression
suggested that gefitinib is cost-effective at WTP 53,000 USD/life-year or higher.
CONCLUSIONS: Among lung cancer patients who started with platinum-based
chemotherapy, followed by taxane-based regimen, adding gefitinib to chemother-
apy is likely to be cost-effective.
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OBJECTIVES: To evaluate the cost-utility of stage III colorectal cancer patients re-
ceiving either capecitabine-based or 5-FU/LV-based adjuvant treatments from the
societal perspective.METHODS: The data used in this research is being reported in
another study (Health Related Quality of Life, Direct and Indirect Cost Analysis of
Stage III Colorectal Cancer Patients Receiving Different Adjuvant Chemotherapy
Treatments in Taiwan). Direct and indirect costs, including productivity loss of
patients and their accompanying persons caused by receiving outpatient or inpa-
tient services, were involved in this study. Propensity score matching was used to
reduce selection bias and avoid endogenous problems between two groups of pa-
tients. The perspective adopted in this analysis was that of a society in Taiwan. All
costs were expressed in 2011 New Taiwan dollars (1 USD is about 30 NTD). Utility
value for the health states were derived by mapping the 16 dimensions of EORTC
QLQ-C30 onto the EQ-5D based on the published literature (McKenzie and van der
Pol, 2009). RESULTS: After propensity score matching, a total of 219 patients were
included in the analyses. There are 109 in the capecitabine-based treatment and
110 in the 5-FU/LV-based treatment. Over the study period of 6months, the average
cost of capecitabine-based treatment per patient was NT$220,576.3 while yielding
0.47 quality-adjusted life years (QALY). On the other hand, the average cost of
5-FU/LV-based treatment was NT$566,832.1 with 0.42 QALY. Between these two
adjuvant treatments, the capecitabine-based treatment was dominant.
CONCLUSIONS: As opposed to existing studies, cost and HRQoL data were directly
obtained from patients. Thus, based on patient-level information and the from the
societal perspective, our study showed that capecitabine-based treatment not only
saved costs but also improved quality-adjust life year compared with 5-FU/LV-
based treatment in the adjuvant treatment of stage III colorectal cancer in Taiwan.
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OBJECTIVES: Lung cancer is the common cause of cancer death in developing
countries. In Thailand, lung cancer, including non-small cell lung cancer (NSCLC)
ranks third of 10 leading sites of cancers. NSCLC has a poor prognosis which has an
effect on quality of life of both individual patients and their family. Understanding
the quality of life andhealth utility for lung cancer is important; however, little data
are available in Thailand. This study aimed to measure baseline health utility
among advance NSCLC patients before treated with first-line chemotherapy.
METHODS: A prospective cohort study was implemented in Maharaj Nakorn
Chiang Mai hospital which is a medical teaching hospital located in the north of
Thailand. A variety of first-line chemotherapy regimens were available for treat-
ment. In this study, we included patients aged 18 or above, diagnosed with NSCLC
with stage IIIB and IV, had performance status (ECOG) 0-1, and were scheduled to
receive first-line chemotherapy. The data were collected from January to March
2012. Utility was measured using EuroQoL Thai version. The data were collected
while patients visited outpatient oncology clinic. Descriptive statistics were used
for data analyses. RESULTS: During three months period, 24 patients were in-
cluded. Eight patients were NSCLC stage IIIB while 16 were stage IV. Mean utility
value of overall NSCLC, NSCLC stage IIIB and NSCLC stage IV at baseline before
receiving first-line chemotherapy were 0.419, 0.473 and 0.392, respectively.
CONCLUSIONS: Utility values of patients with advanced NSCLC are likely to be
downward due to the severity of disease; therefore, choosing the appropriate first-
line chemotherapy regimen might need to consider the quality of life of patients.
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OBJECTIVES: Benefits of treatment are often expressed as quality-adjusted life
years (QALYs). A QALY attempts to capture benefit in terms of both quantity of
survival and quality of life (QoL). Where appropriate data has not been captured in
a trial context, other methods need to be applied. The aim of this study was to
capture QoL data in the form of health state utilities, ranging from 0 (dead) to 1 (full
health), for outcomes associated with receiving therapy for rel/ref HL and sALCL.
These utilities could be used to support economic evaluation of future treatments.
METHODS: Health state descriptions or ‘vignettes’ were developed (with patient
and clinician input) depicting the burden associated with various stages of rel/ref
HL or sALCL, degree of disease response (complete [CR] or partial response, stable
or progressive disease), and adverse events (AE) experienced (B-symptoms, acute/
chronic graft-versus-host disease [GVHD], grade I/II or grade III peripheral sensory
neuropathy). Vignettes were then valued by 75 members of the general public in
Taiwan, Thailand, and South Korea using the time trade-off (TTO) methodology to
elicit utility values. RESULTS:Disease experience was associated with a significant
decline in QoL. Even a CR demonstrated a notable negative impact on QoL (Taiwan
0.597, Thailand 0.728, South Korea 0.827). The experience of any AE was associated
with substantial disutility, themost burdensome generally being acute GVHD (Tai-
wan 0.199, Thailand 0.124, South Korea 0.347). Additionally, progressive disease
was valued as having a very severe impact on QoL (Taiwan 0.229, Thailand 0.071,
South Korea 0.317).CONCLUSIONS: Experience of rel/ref HL and sALCL is viewed as
potentially devastating by individuals in all three countries. However, variations do
exist between regions, suggesting that individuals may approach the TTO exercise
differently. The results of this study may have important implications for the eco-
nomic evaluation of future treatments.
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OBJECTIVES: To investigate the cancer patients’ CAM disclosure to the health care
provider.METHODS: The study was designed as a questionnaire based, cross sec-
tional analysis. A prevalence based sample of 393 cancer patients admitted to the
oncology ward at Penang General Hospital was hereby selected for the study.
RESULTS: Of 393 patients, 184 (46.1%) were identified as CAM users and among
them126 (68.5%)were actively reported to use one ormore types of CAMat the time
of interview. CAMdisclosure rate was 43%, while only in 33.7% cases, patients been
asked by their doctors on the CAM use. The most common reason of CAM non-
disclosure was ‘not important for doctors to know about CAM’ 63 (34.2%). Among
other reasons were, ‘doctors never asked about CAM’ 15(8.2%), ‘doctors have little
knowledge about CAM’ 9(5.9%), ‘fear of CAMdisapproval by the doctors’ 8(4.3%) and
fear of termination of therapy by the doctors’ 6(3.3%). Among the demographic
variables patients having a history of regular health checkups before cancer diag-
nosis were tend to discuss their CAM use with the doctors (r0.16, p0.02). Per-
ceived severity of side effects due to conventional therapies was positively corre-
lated (r0.18, p0.014) with CAM disclosure. Patients who received
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recommendations on CAM from friends and family members were tend not to
disclose their CAM use (r -0.17, p0.02). However those received recommenda-
tions from their health care providers were more likely to disclose CAM use (r0.3,
p0.001). Previous experiences of side effects due to CAM therapies was positively
correlated (r0.14, p0.04) with CAM disclosure behavior. CONCLUSIONS: Under-
standing the underlying beliefs of patients’ reluctance to disclose CAM usage to
health care providers is important especially when they are on active cancer treat-
ment. A friendly non-judgmental discussion about CAMuse by the physiciansmay
improve patients’ CAM behavior towards CAM disclosure.
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OBJECTIVES: Since the launch of imatinib in Taiwan, survival of chronic myeloid
leukemia (CML) has significantly improved with the cost of numerously increasing
drug expenditure. Neither health-related quality-of-life (QoL) of CML patients nor
long-term cost-effectiveness of imatinib, however, has been investigated in Tai-
wan. This study aimed to explore the feasibility of preference-based utility mea-
sures on CML patients with imatinib treatment. METHODS: This cross-sectional
survey was conducted at a medical center in southern Taiwan from June 2011 to
January 2012 after approved by the Institutional Review Board. CML outpatients
receiving imatinib were invited to participate the interviews; their QoL were mea-
sured by EuroQol group 5-dimension (EQ-5D) questionnaire, 100-mm visual ana-
logue scale (EQ-5D VAS) and time-trade-off (TTO) method, and then transformed
into utility value. Japanese preference weight was used to transform EQ-5D index
into utility. Patients’ demography, socioeconomic characteristics and progression
history were collected to adjust utility values by multiple regression. RESULTS: Of
the 42 (mean age: 50.016.0 years, male: 54.8%) participants, 36 (85.7%) have been
regularly followed up over 1.5 years, and 13 (31.0%) had history of progressing to
accelerated or blast phase. In EQ-5D survey,most participants choose “no problem”
in the domains of mobility, self-care, and usual activities, and 10 (23.8%) and 7
(16.7%) participants choose “some problem” in pain/discomfort and anxiety/de-
pression, respectively. Mean utility values and response rates for EQ-5D, EQ-5D
VAS, and TTO were 0.800.09 (100%), 0.780.13 (97.6%), and 0.800.18 (92.9%) and
there was no significant difference in utility between three measures. No associa-
tion between participant’ characteristics and utility was found, except for utility
derived from EQ-5D VAS was significantly associated with education level.
CONCLUSIONS: Preference-based utility measured are applicable to CML patients
receiving routine treatments. Since no Taiwanese preference weight for transfer-
ring EQ-5D assessment, further large-scale studies are needed, however, to vali-
date and cross-validate the measurements.
PCN29
HRQOL DURING ADJUVANT CHEMOTHERAPY WITH CAPECITABINE IN
PATIENTS AFTER SURGERY FOR COLON CANCER: ADDITIONAL STUDY OF
JFMC37-0801
Ishiguro M1, Shiroiwa T2, Fukuda T3, Tomita N4
1Tokyo Medical and Dental University, Graduate School, Tokyo, Japan, 2Ritsumeikan University,
Kusatsu, Shiga, Japan, 3National Institute of Public Health, Saitama, Japan, 4Hyogo College of
Medicine, Hyogo, Japan
OBJECTIVES: The JFMC37-0801 trial is a phase III trial designed to validate superi-
ority of 1-year treatment with capecitabine to 6 months treatment as adjuvant
chemotherapy for stage III colon cancer. Health related quality of life (HRQOL) and
cost-effectiveness have been evaluated as an additional study. We analyzed im-
pact of prolonged treatment with capecitabine on patients’ HRQOL. METHODS:
Capecitabine (2500mg/m2/day) was orally given on days 1-14, followed by a 7-day
rest. Enrolled patients were randomly assigned to group A (received 8 courses of
capecitabine) or group B (16 courses). In patients agreed to participate to the addi-
tional study, HRQOL was evaluated by self-administered questionnaire at the start
of the protocol treatment, 3, 6, 9, 12, 15 and 18months. The questionnaire includes
Functional Assessment of Cancer therapy-C (FACT-C) and EuroQol 5 Dimension
(EQ-5D). RESULTS: In 1306 patients enrolled to the JFMC37-0801 trial, HRQOL of 171
participants (81 in group A, 90 in group B) were evaluated. Mean age of the patients
in group A and B was 63.3 and 64.5 years-old, respectively. Among a total of 1197
points of survey, 959 questionnaires (80.1%) were retrieved. Recovery rates of ques-
tionnaires tended to decrease with time after finishing treatment. Through the
entire survey period, mean score of FACT-C (96.9-103) and EQ-5D (0.85-0.93) were
satisfactory. In longitudinal analysis of the change from baseline score, the scores
tended to increase after finishing the treatment period in both group A and group
B. Significant difference between the score of groupAand groupBwasnot observed
in each survey point. No difference by age and tumor stage was also observed.
CONCLUSIONS: HRQOL of the patients received postoperative adjuvant chemo-
therapy with capecitabine was satisfactory through the survey period. There was
no significant difference of HRQOL between 8 and 16 courses of capecitabine treat-
ment.
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OBJECTIVES: Prayers, spiritual healing, yoga, meditation, tai Chi, Qi gong, support
groups are classified as Mind Body Complementary Therapies (MBCTs). While the
benefits of MBCTs in cancer care is continued to be investigated, the prevalence of
such practices is notwell known amongMalaysian cancer patients. The study aims
to examine the prevalence of MBCTs use and its potential effects on Health related
quality of life (HRQoL) in a group of cancer patients. METHODS: This cross-sec-
tional study was undertaken with 393 cancer patients at the oncology wards of
Penang General Hospital, Malaysia. RESULTS: Out of 393 participants, 184 (46.1%)
were reported to use some type of Complementary and Alternative Medicines
(CAM). Among the CAM users, 75(40.7%) patients self reported using MBCTs for
their cancers. The majority of the MBCTs users were female (60/75, p0.01), aged
between 38 and 57 (44/75), and were from Malay ethnicity (46/75). Socio-demo-
graphic factors including age (r0.15, p0.03) and monthly house hold income (r
-0.25, p0.001)were strongly correlatedwithMBCTs use. Prayers for health reasons
was the highest 51 (27.7%), followed by spiritual practices 20(10.8%), meditation
7(5.9%), tai chi 7(3.8%), music therapy 4(2.1%), Qigong 1(0.5%), hypnotherapy
1(0.5%), and reiki 1(0.5%). Recommendations from friends and family members
53(70%) were the most common reasons of MBCTs use followed by patient’s own
will 22(29.3%). Health related Quality of Life (HRQoL) scores shows significant dif-
ference in functional and symptoms scores among MBCTs users and non-users.
CONCLUSIONS:Nearly half of the CAMusers utilized some types ofMBCTs. Prayers
specifically for health reasons and spiritual practices are somewhat common
among cancer patients. Viewing MBCTs not as alternative but to complement can-
cer therapies to address emotional and psychological needsmay help in improving
health related quality of life (HRQoL) of cancer patients.
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OBJECTIVES: To examine the prevalence of CAM use among Malaysian cancer
patients and compare the differences in health-related quality of life (HRQoL) be-
tween CAM users and non-users. METHODS: This cross-sectional study was un-
dertaken with 393 patients at the oncology wards of Penang General Hospital,
Malaysia. The HRQoL between CAM users and non-users was assessed by using
European Organization for Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLQ-C30). RESULTS: The majority (46.1%) of the participants
were frequent CAM users. The most common CAM therapies were dietary and
nutritional supplements (41.3%), herbal products (30.4%), prayers for health rea-
sons including spirituality (22.8%), traditional Malay therapies (20.11%) and Tradi-
tional Chinese Medicines (14.1%). No significant difference was found between
functional and symptoms scores among CAM users and non-users. However;
global health scores/quality of life was significantly different (P0.002) between
CAM users and non-users. CONCLUSIONS: Patients’ interest in the use of CAM
highlights the need of greater health care education in this field. This study pro-
vides evidence of CAM use and its overall effects on quality of life scores in a
sample of patients with cancer. Patients should be aware of the potential benefits
of CAM therapies for cancer. Health care professionals can play their role effec-
tively to encourage patients towards rational use of CAM therapies.
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OBJECTIVES: To assess quality of Life (QoL) among cancer patients receiving cape-
citabine at Nakhon Pathom Hospital in Thailand. METHODS: Cancer patients re-
ceiving capecitabine, either as monotherapy or in combination with other anti-
cancer drugs, at Nakhon PathomHospital, were recruited during July to September
2011. The Thai version of the Functional Assessment of Cancer Therapy-General
(FACT-G) comprising four subscales, physical well-being (PWB), social/family well-
being (SWB), emotional well-being (EWB) and functional well-being (FWB), was
utilized to assess QoL of these patients. Demographic data (age, gender,status,
educational level, occupation, and monthly income) as well as medical history
(type, stage and duration of cancer) of the patients were also collected. RESULTS:
Altogether 13 patients receiving capecitabinemonotherapy and 24 patients receiv-
ing capecitabine combination therapywere recruited in this study. Theirmean (SD)
overall QoL score was 51.66 (9.33) from 108 . While the mean (SD) scores for PWB,
SWB, EWB and FWB subscales were 8.60 (5.86), 19.91 (5.75) from 28, 7.38 (4.96) from
24 and 15.77 (7.88) from 28, respectively. The mean QoL in this group of patients
were lower than normaltive data. Only subscal SBW that higher than normative
data. The score of BEWPWBFWBSWB. No significant relationship was re-
vealed between demographic data and any subscales of the FACT-G in patients
receiving capecitabine monotherapy, CONCLUSIONS: The QoL in patients who
receive capecitabinemonotherapy are lower thannormative data. Even though , no
relationships are found between demographic data and any subscales. The activ-
ities to improve patients’ emotion should be establish to improve quality of life of
the patients.
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